癌基因调控。通过非编码基因间元件的体细胞突变形成的致癌超级增强子。

Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.

机构信息

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Department of Haematology, UCL Cancer Institute, University College London, London WC1E 6BT, UK.

Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.

出版信息

Science. 2014 Dec 12;346(6215):1373-7. doi: 10.1126/science.1259037. Epub 2014 Nov 13.

Abstract

In certain human cancers, the expression of critical oncogenes is driven from large regulatory elements, called super-enhancers, that recruit much of the cell's transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene. MYB binds to this new site and recruits its H3K27 acetylase-binding partner CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP, which suggests a general role for MYB in super-enhancer initiation. Thus, this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells.

摘要

在某些人类癌症中,关键癌基因的表达是由称为超级增强子的大型调节元件驱动的,这些元件招募了细胞的大部分转录装置,并通过组蛋白 H3 赖氨酸 27(H3K27ac)的广泛乙酰化来定义。在一小部分 T 细胞急性淋巴细胞白血病(T-ALL)病例中,我们发现获得了杂合体细胞突变,这些突变在一个精确的非编码位点引入了 MYB 转录因子的结合基序,从而在 TAL1 癌基因的上游创建了一个超级增强子。MYB 结合到这个新位点,并招募其 H3K27 乙酰化酶结合伙伴 CBP,以及包含 RUNX1、GATA-3 和 TAL1 自身的主要白血病转录复合物的核心组件。此外,在 T-ALL 细胞中发现的大多数内源性超级增强子都被 MYB 和 CBP 占据,这表明 MYB 在超级增强子起始中具有普遍作用。因此,这项研究确定了导致恶性细胞中致癌超级增强子产生的遗传机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索